Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
24.98
+0.27 (1.09%)
At close: Feb 17, 2026, 4:00 PM EST
24.94
-0.04 (-0.16%)
After-hours: Feb 17, 2026, 4:10 PM EST
Centessa Pharmaceuticals Employees
Centessa Pharmaceuticals had 114 employees as of September 30, 2025. The number of employees increased by 39 or 52.00% compared to the same quarter last year.
Employees
114
Change
39
Growth
52.00%
Revenue / Employee
$131,579
Profits / Employee
-$2,128,930
Market Cap
3.65B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 114 | 39 | 52.00% |
| Jun 30, 2025 | 98 | 26 | 36.11% |
| Mar 31, 2025 | 86 | 9 | 11.69% |
| Dec 31, 2024 | 77 | 1 | 1.32% |
| Sep 30, 2024 | 75 | 0 | - |
| Jun 30, 2024 | 72 | 8 | 12.50% |
| Mar 31, 2024 | 77 | -5 | -6.10% |
| Dec 31, 2023 | 76 | -7 | -8.43% |
| Sep 30, 2023 | 75 | 7 | 10.29% |
| Jun 30, 2023 | 64 | -4 | -5.88% |
| Mar 31, 2023 | 82 | -8 | -8.89% |
| Dec 31, 2022 | 83 | -7 | -7.78% |
| Sep 30, 2022 | 68 | -2 | -2.86% |
| Jun 30, 2022 | 68 | 23 | 51.11% |
| Mar 31, 2022 | 90 | 45 | 100.00% |
| Dec 31, 2021 | 90 | - | - |
| Sep 30, 2021 | 70 | - | - |
| Jun 30, 2021 | 45 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| ADMA Biologics | 685 |
| ACADIA Pharmaceuticals | 654 |
| Xenon Pharmaceuticals | 327 |
| Alumis | 223 |
| Liquidia | 170 |
| Arcellx | 163 |
| Erasca | 103 |
CNTA News
- 5 days ago - Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals - GlobeNewsWire
- 14 days ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting - GlobeNewsWire
- 5 weeks ago - Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program - GlobeNewsWire